---
title: Surface pTÎ± expression predicts LCK activation and preclinical synergy of LCK
  and JAK coinhibition in adult T-ALL
date: '2025-02-20'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39977715/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20250221170832&v=2.18.0.post9+e462414
source: Blood
description: Refractory and/or relapsing T-cell acute lymphoblastic leukemia (T-ALL)
  remains a major therapeutic challenge. The pre-TCR pathway has recently emerged
  as a therapeutic target via LCK inhibition in this context. However, there is a
  need for simple and quickly assessable biomarkers to predict sensitivity to LCK
  inhibitors. Moreover, targeting LCK alone by tyrosine kinase inhibitors, such as
  Dasatinib, often results in transient clinical responses, emphasizing the need for
  efficient ...
disable_comments: true
---
Refractory and/or relapsing T-cell acute lymphoblastic leukemia (T-ALL) remains a major therapeutic challenge. The pre-TCR pathway has recently emerged as a therapeutic target via LCK inhibition in this context. However, there is a need for simple and quickly assessable biomarkers to predict sensitivity to LCK inhibitors. Moreover, targeting LCK alone by tyrosine kinase inhibitors, such as Dasatinib, often results in transient clinical responses, emphasizing the need for efficient ...